Login to Your Account

Array Licenses TLR Program To VentiRx, Keeps Cancer Option

By Trista Morrison

Wednesday, March 14, 2007
A week after closing a $26.6 million Series A financing to acquire Toll-like receptor (TLR) assets, VentiRx Pharmaceuticals Inc. licensed a preclinical TLR program from Array BioPharma Inc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription